Renal operationally tolerant patients (TOL) display a defect in B cell differentiation, with a deficiency in plasma cells. Recently described, T follicular helper (Tfh) cells play a critical role in B cell differentiation. We analyzed blood Tfh subsets in TOL and transplanted patients with stable graft function under immunosuppression (STA). We observed a reduced proportion of blood activated and highly functional Tfh subsets in TOL, without affecting Tfh absolute numbers. Functionally, Tfh cells from TOL displayed a modified gene expression profile, failed to produce interleukin-21, and were unable to induce IgG production by naive B cells. This Tfh defect is linked to a low incidence of postgraft de novo donor-specific antibody (dnDSA) immunization, suggesting that the lack of Tfh cells in TOL may induce a protolerogenic environment with reduced risk of developing dnDSA. Finally, we showed that elevated Tfh in STA precedes the occurrence of dnDSA during an alloresponse. These data provide new insights into the mechanisms of antibody response in operational tolerance. Disrupted homeostasis and impaired Tfh function in TOL could lead to a reduced risk of developing dnDSA and suggest a predictive role of blood Tfh cells on the occurrence of dnDSA in transplant recipients.
Introduction
Although the need to maintain transplanted patients on immunosuppression is universally recognized, long-term renal graft outcome is limited by the side effects of immunosuppressive drugs themselves (1) (2) (3) (4) (5) (6) . While recent advances have been described that favor tolerance induction in renal transplantation (7) , to date, no immunosuppression minimization protocol has been established or validated. Interestingly, the long-term acceptance of a mismatched kidney allograft after immunosuppressive drug withdrawal, defined as operational tolerance in humans, can occasionally be observed and is principally as a result of patient noncompliance (8) (9) (10) (11) . Identifying renal transplant recipients with stable graft function under a standard immunosuppression regimen (STA) who could benefit from drug minimization remains a real challenge. Comprehensive immune characterization of patients defined as operationally tolerant (TOL) should help us to reach this challenge. Analyses of TOL blood indicate B cells are important in the development and/or maintenance of tolerance (12) (13) (14) (15) (16) (17) (18) (19) . We reported that B cells from TOL did not fully differentiate into plasma cells, whereas cells from STA did, which could contribute to a protolerogeneic environment (13) . However, the precise mechanisms involved in this B cell differentiation defect in TOL remain to be fully characterized.
Follicular helper T (Tfh) cells localize in the lymphoid organs and are crucial for supporting B cell differentiation (20) . Obtaining lymph node samples from patients is extremely challenging; therefore, several studies have focused on studying blood CD4 + T cells expressing the CXCR5 chemokine receptor, which shares functional properties with Tfh cells localized in lymphoid tissues (21, 22) . The phenotype and function of blood Tfh cells have been principally analyzed in autoimmunity and infectious diseases (23) (24) (25) . In the field of organ transplantation, Tfh cells are involved in humoral alloreactivity (26) (27) (28) , but their possible role in TOL has not been described. In the current study, we measured the percentage and function of blood Tfh cells in TOL compared with in STA patients and identified a decreased proportion of blood Tfh cells in TOL, particularly the activated and highly functional subsets. Moreover, we showed that they were functionally impaired when cocultured with naive B cells and lacked interleukin (IL)-21 production. Finally, we suggest that blood Tfh characterization can be potentially used to predict the occurrence of de novo DSA (dnDSA) in transplant recipients.
Materials and Methods

Patients
Two groups of kidney transplant recipients were included in the study: (1) TOL patients with stable kidney graft function (creatinemia <150 lmol/L and proteinuria <1 g/24 h) in the absence of immunosuppressive treatment for at least 1 year (n = 8) and (2) STA recipients with proteinuria <0.5 g/24 h and stable creatinemia for at least 1 year (creatinemia <150 lmol/L or <200 lmol/L with a variation <20% of the mean value of creatinemia in the year preceding inclusion) (n = 14) ( Table 1) . For the retrospective analysis, we selected 60 patients from the multicentric Donn ees Informatis ees et Valid ees en Transplantation database with stable graft function (creatinemia <150 lmol/L and proteinuria <0.5 g/24 h at 3, 6, and 12 months posttransplantation) and without dnDSA at 1 year posttransplantation. Among the 60 patients, seven developed dnDSA and 53 patients had no dnDSA during the follow-up ( Table 2) .
Immunophenotyping of blood Tfh cells
Tfh cells were characterized from peripheral blood mononuclear cells (PBMCs) through flow cytometry (BD LSRII) with the following antihuman monoclonal antibodies: anti-CD4 PerCP Cy5. ) were sorted by using a BD FACSAria (BD Biosciences). Purity was always >95%. Total RNA from sorted blood Tfh cells was extracted by using the TRIzol procedure (according to manufacturer's protocol; Invitrogen). Transcriptome analysis was performed according to the SmartSeq2 protocol (29, 30) with some modifications (31) . Expression values are expressed in fragments per kilobase million.
T cell receptor Vb repertoire analysis of purified blood Tfh
After reverse transcription using M-MLV Reverse Transcriptase (Invitrogen), 17 T cell receptor (TCR) Vb transcripts were quantified by qRT-PCR (7900 Real-time PCR; Applied Biosystem) and expressed according to the standard procedure of -2 ddCt , using HPRT as reference gene. The CDR3 length distribution of each individual Vb family was obtained using a capillary sequencer (3730 Applied Biosystem). The CDR3 length distribution of each Vb family was classified in a nonbiased manner as either polyclonal or oligoclonal as peviously described (32) . Additionally, qualitative analysis was measured for an additional 13 TCR Vb families. Reproducibility and accuracy were assessed at each step of the TCR Vb repertoire analysis. Software developed to automatically describe individual TCR Vb profiles was used (32) .
Cytokine and Ig production in Tfh-B cell coculture assays 
Statistics
Statistical analyses were performed using GraphPad Prism software. TOL and STA recipient groups were compared using the nonparametric Mann-Whitney test or v 2 test for quantitative or qualitative parameters, respectively. Significance was defined as a p-value < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001). Spearman correlation coefficient and twotailed p-values were determined in the analysis of correlations. Survival analysis was performed using the Kaplan-Meier method and the log-rank test for significance.
Results
Clinical characteristics of kidney recipients Table 1 lists the baseline characteristics of the operationally tolerant patients (TOL, n = 8) and the patients with stable graft function under immunosuppression (STA, n = 14) for which we performed immunophenotyping, RNA sequencing, and TCR Vb repertoire analysis. As previously described (8, 10) , and inherent to the status of operationally tolerant recipients, a lower proportion of TOL received induction therapy (57% vs. 100%, p = 0.03) and had a longer time of transplantation compared with STA (20.7 vs. 6.8 years, p < 0.001).
TOL recipients harbor a quantitative Tfh defect, which affects activated and highly functional Tfh cell subsets We first determined the percentage of CD4 Note that these latter experiments were performed on frozen PBMCs. PBMC, peripheral blood mononuclear cell; PD-1, programmed cell death-1; ICOS, Inducible T-cell Costimulator; STA, renal transplant recipient with stable graft function under immunosuppression regimen; TOL, operationally tolerant recipients.
with percentage, absolute numbers of Tfh and subsets of Tfh were not different between the two groups of transplanted recipients ( Figures 1A and B) .
Because the TOL group had a longer time of transplantation compared with STA (20.7 vs. 6.8 years, p < 0.001), we next investigated whether the percentage of blood Tfh cells was influenced by time posttransplantation. As shown in Figure 1C , no correlation was found between time after transplantation and the percentage of Tfh cells in both groups of patients. We performed additional experiments to evaluate the changes related to time posttransplantation. No difference was found regarding percentage of Tfh cells between two groups of patients with a mean of 5.2 AE 0.2 and 14.9 AE 1.0 years posttransplantation ( Figure 1D ) and regarding Tfh proportion at a year's interval in a cohort of 35 STA recipients (data not shown), strengthening the fact that time after transplantation probably did not affect the percentage of Tfh cells. Altogether, these results highlight a quantitative defect of Tfh that particularly affects activated and highly functional subsets in the blood from TOL compared with STA recipients, without any differences regarding absolute numbers.
Blood Tfh cells from TOL exhibit a modified gene expression profile We next compared purified blood Tfh cell gene expression by RNA-seq for the two groups of patients. Overall, 16 273 transcripts were expressed in blood Tfh cells from both groups. To compare the Tfh gene expression profile between TOL and STA, we used the top 100 gene signature of blood Tfh cells published by Locci et al (21) . Among these 100 genes differentially expressed between Tfh and non-Tfh cells from healthy volunteers, 77 were expressed in our samples. Among them, 17 genes were differentially expressed between TOL and STA (p < 0.05) and were hierarchically clustered. Among these, six genes upregulated in Tfh from healthy volunteers in Locci et al's study were downregulated in TOL and, inversely, 11 genes downregulated in Tfh cells from healthy volunteers were upregulated in TOL (Figure 2A) . Moreover, expression of BCL6, the master regulator of Tfh differentiation, as well as other transcription factors associated with T cell differentiation (including TBX21, GATA3, RORC, and FOXP3) was not different between the two groups of transplant patients ( Figure 2B ). Finally, using gene set enrichment analysis, and particularly focusing on immunological signatures, we identified 21 and 26 gene sets associated with TOL and STA, respectively (FDR <5%), with two main biological functions: (1) genes associated with Th2 differentiation (upregulated in TOL and downregulated in STA) (33) and (2) genes upregulated after in vitro CD4 + T cell activation (34,35) (upregulated in TOL and downregulated in STA) (Tables  S1A and B) . Collectively, the transcript data indicate that Tfh from TOL exhibit a modified Tfh gene expression profile, which is more polarized toward a Th2 transcript profile.
TOL Tfh cells exhibit a Gaussian use of their TCR Vb repertoire Antigen-driven T cell expansion results in the accumulation of specific TCR Vb families and the selection of a specific CDR3 length distribution (36) (37) (38) . To explore antigen-driven selection of Tfh cells on the basis of a preferential TCR use, the TCR Vb repertoire of purified Tfh cells from TOL and STA was analyzed. Quantitatively, the frequency of each Vb family (17 families) was similar regardless of the TOL and STA groups (minimal frequency = 5.12; maximal frequency = 8.45; Figure S1A ). No increase in one or several Vb families was observed, thereby demonstrating the absence of selection and clonal expansion of a specific Vb family in Tfh purified from TOL and STA. This was confirmed by the polyclonal CDR3 pattern of the TCR Vb families in Tfh purified from TOL or STA ( Figure S1B) . Altogether, the TCR Vb repertoire of both groups remained Gaussian, suggesting no antigen-selection of Tfh.
TOL blood Tfh cells cocultured with B cells express reduced IL-21 and are not able to induce B cell IgG production
To determine whether Tfh cells can provide B cell help, we cocultured autologous blood Tfh and naive B cells in vitro. We first assessed B cell proliferation in the presence of Tfh (1:1 ratio) at day 4 by using flow cytometry. As shown in Figure 3A , the number of proliferative B cells was similar between TOL and STA. Similarly, no difference in the number of plasmablasts (CD4 À CD20 À CD38 + cells) or viable B cells was detected on day 7 ( Figure 3B ). Nonetheless, on day 7, blood Tfh cells from TOL were significantly less potent at inducing naive B cell IgG production compared with STA ( Figure 3C , p < 0.05). Tfh cells are essential for the generation of antibodies. Increased percentage of blood Tfh cells is observed in patients with autoimmune diseases or in HIV-infected patients, with a positive correlation between proportion of Tfh cell and antibody production (21, 39) . Thus, the failure of Tfh cells from TOL to provide help to naive B cells was not due to reduced numbers of Tfh cells, given that Tfh cells from STA and TOL survived similarly in coculture ( Figure 3D) . Interestingly, the defective IgG production in TOL was associated with a significant decrease in the level of Tfh IL-21 secretion in cocultures compared with STA ( Figure 3E, p = 0.03) . Altogether, these data suggest that Tfh cells from TOL produce less IL-21 and do not induce B cell IgG production.
Postgraft DSA immunization is rare and delayed in TOL The altered function of blood Tfh cells from TOL in vitro raises the question whether such a defect may have consequences in vivo, by decreasing the incidence of dnDSA production. We have previously described a cohort of 27 TOL, focusing on their clinical characteristics (10) . Based on this initial report, we updated the data with respect to the occurrence of dnDSA and graft dysfunction, as defined by a creatinine clearance <30 mL/min/1.73 m Figure 4C shows the Kaplan Meier kidneyallograft survival curve according to dnDSA status. Median graft survival for patients with dnDSA was significantly lower than the no dnDSA group (21 vs. 39 years, p = 0.003), which is consistent with other studies in stable patients under immunosuppression, even when considering the low number of such rare patients (40) (41) (42) . Collectively, this data shows that only a few TOL developed dnDSA, and that the post graft immunization in TOL occurs late after transplantation with a negative impact on their graft function.
Blood Tfh cell counts are higher at 1 year posttransplantation in stable transplant patients who subsequently developed dnDSA We propose that the blood Tfh defect in TOL recipients could drive a protolerogenic environment that results in reduced postgraft dnDSA immunization. We subsequently hypothezised that highly functional blood Tfh cells in stable transplant recipients could be more potent at inducing dnDSA and that the occurrence of dnDSA may be preceded by an increased proportion of blood Tfh cells in order to support B cell differentiation toward plasma cell secreting dnDSA. To test this, we compared the proportion of blood Tfh cells from 60 stable transplant recipients with no dnDSA at 1 year posttransplantation and who developed dnDSA (dnDSA + , n = 7) or did not (dnDSA À , n = 53) during the follow-up ( Figure 5A ). Note that the incidence of dnDSA immunization within 10 years posttransplantation was higher in this STA cohort (7/60, 12%) compared with the group of 27 TOL (1/27, 4%). In accordance with the literature (40), the 10-year graft survival for dnDSA + patients was lower than that of the dnDSA À group (54% vs. 91%, p = 0.001, Figure 5B) . Comparisons between the two groups are summarized in Table 2 . As noted in Figure 5C and in accordance with our hypothesis, the proportion of Tfh cells was higher in the dnDSA + group compared with the dnDSA À group ( Figure 5C , p = 0.03). Altogether, these data show that blood Tfh quantification in patients with stable graft function is of interest for following postgraft dnDSA immunization over time, which is correlated with worse graft outcome.
Discussion
Operational tolerance is a rare phenomenon in kidney transplantation (10, 11) . Several studies, including ours, have highlighted an important B cell signature (12, (14) (15) (16) (17) (18) (19) , with a notable defect in terminal B cell differentiation (13) . We focused on Tfh cells, which express surface molecules favoring cognate B cell interactions and are specialized in providing B cell help (20, 43) . We identified and characterized blood Tfh cells from TOL recipients in order to decipher their potential role in B cell-mediated immune responses compared with stable transplant recipients under immunosuppression. classification based on blood Tfh profiles from healthy individuals (21) . This TOL profile is not associated with the longer time of transplantation within this group, as shown by the lack of correlation between the two parameters. In contrast with percentage, absolute numbers are not different between the two groups of transplanted recipients. This is not surprising regarding what happens, for example, for regulatory T cells in the same population of patients, with an increased percentage of CD4 + CD45RA À Foxp3 hi memory regulatory T cells (data not shown), as previously reported by Braza et al (44) . We clearly have a protolerogenic T cell balance in TOL with a reduced percentage of effector T cells (45) and an increased percentage of regulatory T cells (44) , which contribute to the establishment of a favorable protolerogenic T cell environment, independent of the absolute numbers of cells. In this particular situation of tolerance to an allogeneic transplant, this quantitative defect of circulating Tfh was also associated with a "qualitative" defect with a significant failure to induce IgG production by naive B cells compared with Tfh cells from STA. Interestingly, the intrinsic function of Tfh cells is not involved in this defect, as shown by the Th2 transcript profile and by the Th2 cytokine polarization profile of Tfh cells from TOL on polyclonal stimulation (data not shown), which correspond to the highest functional subsets (22, 23) .
We also report on a Gaussian TCR repertoire in Tfh cells from TOL, suggesting no antigen selection of Tfh subset and an overall state of defective Tfh response. Based on this result, a genetic predisposition concerning Tfh genes related in TOL could be hypothesized. However, it is well established that TOL are not immunosuppressed (8, 10, 11, 46) and have a profile of "tolerance" likely due to a fine tuning of their immune system toward a regulatory profile, which is consistent with the protolerogenic CD4 + environment as previously mentioned. Moreover, mutations concerning genes involved in Tfh cell differentiation and/or Tfh-B cell interaction (e.g. ICOS, SH2D1A, CD40-CD40L) result in primary immunodeficiency diseases and are associated with severe opportunistic infections (47) (48) (49) , contrary to what was observed in TOL. Of course, the most convincing experiment such as an in vitro assay to measure the response of recipient Tfh cells against self-restricted alloantigen using donor spleen lysates would have been better. Unfortunately, it is not possible to have access to such material in this specific population. (53) . The same authors reported that this reciprocal interaction is dependent on plasmablast IL-6 production, in both humans and mouse models (53). Our results do not support this last hypothesis, as no difference was observed in the number of plasmablasts on day 0 and the level of IL-6 on day 7 between TOL and STA in the cocultures (data not shown). Alternatively, these data suggest a possible positive feedback mechanism, whereby plasmablasts may interfere with Tfh cells at different sites.
To glean insight into the in vivo relevance of our in vitro findings in such a specific and unique situation of tolerance, we chose to investigate the role of Tfh-B cell interactions and their time relationship with humoral alloreactivity in transplanted patients with stable graft function. Tfh cells have been reported to be involved in humoral alloreactivity in animal models (26, 27) and in renal transplant patients (28) . Whether early quantitative and/or qualitative blood Tfh cell defects may directly affect the incidence of specific dnDSA in transplant recipients in vivo has never been explored. Only 19% of TOL from the cohort previously described by Brouard et al (10) developed dnDSA at a median time of 15 years after transplantation. Moreover, only one TOL (4%) developed dnDSA within 10 years posttransplantation, whereas 25% of patients with stable graft function have been described to do so (41) . These observations suggest that the defect in blood Tfh cells observed in blood from tolerant patients may lead to a protolerogenic environment with minimal postgraft DSA immunization levels in these patients. Conversely, these new data also reveal the negative impact of dnDSA on TOL graft function after the loss of operational tolerance. Our data fit with numerous studies during the past decade reporting on the negative impact of dnDSA on allograft outcomes (40, 42, (54) (55) (56) . These show that tolerant patients do not discredit the rule that the control of the mechanisms leading to DSA production could be the central event of the operational tolerance status.
Interestingly, it has been reported that patients with preexisting dnDSA displayed elevated peripheral Tfh cells after transplantation compared with patients with no dnDSA (28) . But, to our knowledge, no study reported on the risk to produce dnDSA according to the proportion of Tfh cells. Based on our observations, we hypothesize that the highly functional blood Tfh cells in some stable transplant patients could be more potent at inducing dnDSA. We carefully selected a cohort of stable transplant patients with or without dnDSA and, in this context, we reported that stable transplant patients who will develop dnDSA in the years after transplantation display a higher proportion of Tfh cells at 1 year posttranspantation and worse graft outcome compared with those who will not develop dnDSA. These data should be treated cautiously considering the small number of patients with dnDSA, but they suggest that quantifying blood Tfh cells during posttransplantion follow-up could assist the clinician in predicting dnDSA immunization and graft outcome.
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